Confirmatory Study for AD-810N in Patients with Parkinsonism in Dementia with Lewy Bodies.

Confirmatory Study for AD-810N in Patients with Parkinsonism in Dementia with Lewy Bodies.(Phase 3 study)

Status

Unknown

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080222787

Enrollment

300

Registered

2015-03-09

Start date

2015-03-09

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinsonism in Dementia with Lewy Bodies

Interventions

investigational material(s) Generic name etc : AD-810N INN of investigational material : Zonisamide Therapeutic category code : 116 Antiperkinsonism agents Dosage and Administration for Investigationa

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Patients met the diagnostic criteria of probable DLB - Outpatients - Patients taking L-DOPA/DCI in succession more than 12 weeks etc.

Exclusion criteria

Exclusion criteria: - Patients with parkinsonism excepting Dementia with Lewy Bodies - Patients with Parkinson's disease with dementia - Epileptic patients - Patients treated with zonisamide etc.

Design outcomes

Primary

Measure	Time frame
Efficacy : UPDRS Part III total score Change in UPDRS Part III total score	—

Secondary

Measure	Time frame
Efficacy : MMSE total score, etc Change in MMSE total score, etc	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026